National Guideline Clearinghouse | Clinical Pharmacogenetics Implementation Consortium guidelines for <em>CYP2C9</em> and <em>HLA-B</em> genotypes and phenytoin dosing.
Clinical Pharmacogenetics Implementation Consortium
Guideline Title
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
Bibliographic Source(s)
Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. [36 references] PubMed |
Guideline Status
This is the current release of the guideline.
This guideline meets NGC's 2013 (revised) inclusion criteria.
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. - PubMed - NCBI
Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
Caudle KE1, Rettie AE2, Whirl-Carrillo M3, Smith LH4, Mintzer S5, Lee MT6, Klein TE3, Callaghan JT7; Clinical Pharmacogenetics Implementation Consortium.
No hay comentarios:
Publicar un comentario